Log in to search using one of your social media accounts:

 

Flu warning: Your persistent cough could be THIS deadly genetic condition
FLU symptoms include a cough and stuffy nose, but they are also signs of a deadly genetic condition called cystic fibrosis. (Source: Daily Express - Health)
Source: Daily Express - Health - September 21, 2017 Category: Consumer Health News Source Type: news

Read Jimmy Kimmel ’s Moving Healthcare Monologue That Everyone’s Talking About
On Tuesday night, Jimmy Kimmel took to his late night show once more to talk healthcare — a subject near and dear to him personally, after his infant son dealt with heart surgery in the days after his birth last May. He delivered a heartfelt monologue then about the importance of adequate health coverage for all Americans, and in the wake of new healthcare legislation from Senators Bill Cassidy and Lindsay Graham, he returned to the subject with an emotional plea. I know you guys are going to find this hard to believe, but a few months ago, after my son had open heart surgery, which was something I spoke about on the...
Source: TIME.com: Top Science and Health Stories - September 20, 2017 Category: Consumer Health News Authors: Raisa Bruner Tags: Uncategorized Healthcare Jimmy Kimmel Late Night Television Source Type: news

Air Pollution Linked to MRSA Acquisition in Children With CF Air Pollution Linked to MRSA Acquisition in Children With CF
Young cystic fibrosis patients chronically exposed to air pollution may be more likely to acquire MRSA, a new study reports.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 20, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Bacteremia and Fungemia in CF Patients With FPE Bacteremia and Fungemia in CF Patients With FPE
Are these pathogens present in cystic fibrosis patients experiencing febrile pulmonary exacerbation?BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

The Emergence of Streptococcus anginosus Group as a Cystic Fibrosis Pathogen
Molecular profiling studies have identified potential emerging pathogens, such as Streptococcus anginosus group, that may play a role in cystic fibrosis (CF) lung disease by either directly causing infection or upregulating the virulence factors of classic CF pathogens, such as Pseudomonas aeruginosa. Routine surveillance of CF pathogens using traditional microbiology culture guides treatment and management of CF patients; however, routine CF culture protocols have not been modified to select for, detect, and further determine the role these emerging pathogens play in the progression of CF lung disease. (Source: Clinical M...
Source: Clinical Microbiology Newsletter - September 7, 2017 Category: Microbiology Authors: Emily M. Hill Source Type: news

Atlant Clinical to Complete Phase II Study in Patients with Cystic Fibrosis
Atlant Clinical has successfully completed an international, multicenter, randomised, placebo-controlled study in patients with cystic fibrosis. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

ProQR concludes QR-010 dosing in Phase Ib trial to treat cystic fibrosis
The Netherlands-based ProQR Therapeutics has concluded dosing patients in a Phase Ib clinical trial of QR-010 for the treatment of patients with cystic fibrosis. (Source: Drug Development Technology)
Source: Drug Development Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news

Scientists can now grow 'mini organs' for each patient
A Dutch lab is growing mini organs for cystic fibrosis patients to see how drugs would affect them without the risks of trying it. Els van de Heijden (pictured) is one of their patients. (Source: the Mail online | Health)
Source: the Mail online | Health - August 23, 2017 Category: Consumer Health News Source Type: news

Lab-made "mini organs" helping doctors treat cystic fibrosis
Doctors in the Netherlands are taking a novel approach to treat cystic fibrosis: They're growing miniature organs for every patient in the country. (Source: ABC News: Health)
Source: ABC News: Health - August 23, 2017 Category: Consumer Health News Tags: Health Source Type: news

Sweet! Sugar-coated probe yields better acid test
(Michigan Technological University) When our cells' acid-alkaline balance goes wrong, it can go wrong in a big way--think cancer and cystic fibrosis. New fluorescent probes make it easier to detect pH and sweetened the deal by adding sugar to his acid-sensitive probes, making them much friendlier to living tissue. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 11, 2017 Category: Cancer & Oncology Source Type: news

'Keep them well': New cystic fibrosis medications move closer to a cure
Results of a new drug trial suggest the next generation of medications, known as CFTR modulators, show potential to correct the genetic defect that causes cystic fibrosis and halt the disease's destructive progression. (Source: CBC | Health)
Source: CBC | Health - August 7, 2017 Category: Consumer Health News Tags: News/Health Source Type: news

Rugby Laboratories Issues Voluntary Nationwide Recall of Diocto Liquid and Diocto Syrup Manufactured By PharmaTech, LLC Due to Possible Product Contamination
Rugby ® Laboratories of Livonia, MI is voluntarily recalling all lots within the expiry of Diocto Liquid and Diocto Syrup, (docusate sodium solutions) manufactured by PharmaTech, LLC of Davie, FL due to a risk of product contamination with Burkholderia cepacia. If a product contains B. cepacia, its use c ould result in infections in patients with compromised immune systems and in patients with chronic lung conditions such as cystic fibrosis. Some of these infections may be serious or even life-threatening in the at-risk patient population. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 3, 2017 Category: Food Science Source Type: news

End of genetic diseases? Congenital heart disease removed from embryos for the first time
INHERITED illnesses from cancer to cystic fibrosis could be wiped out after congenital heart disease was removed from embryos for the first time. (Source: Daily Express - Health)
Source: Daily Express - Health - August 2, 2017 Category: Consumer Health News Source Type: news

Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 Million
Financing to support advancement of novel disease-modifying therapy targeting genetic diseases, including cystic fibrosis SAN DIEGO and REHOVOT, Israel, Aug. 2, 2017 -- (Healthcare Sales & Marketing Network) -- Sevion Therapeutics, Inc. (OTCQB: SVON) a... Biopharmaceuticals, Venture Capital Eloxx Pharmaceuticals, Cystic Fibrosis, Duchene Muscular Dystrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 2, 2017 Category: Pharmaceuticals Source Type: news

Respiratory Microbiome May Influence Inflammation in CF
Less diversity linked to lower IL - 8 concentration, neutrophil count in infants with cystic fibrosis (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - July 31, 2017 Category: Respiratory Medicine Tags: Infections, Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news

Sweat test developed to identify cystic fibrosis in infants
Researchers have developed a method to test the chemical composition of sweat to test for cystic fibrosis in screen-positive infants. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 31, 2017 Category: Consumer Health News Source Type: news

Scientists discover biomarkers which could lead to better treatments for CF pat
(McMaster University) Researchers have identified two new biological markers of cystic fibrosis (CF), a genetic disease which affects children and young adults, leaving them with lifelong health complications including digestive problems and persistent lung infections.The findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 31, 2017 Category: International Medicine & Public Health Source Type: news

Toward a better sweat test for babies with cystic fibrosis
(American Chemical Society) Cystic fibrosis (CF) is an incurable genetic disease in which patients have chronic lung infections. The sooner CF is diagnosed, the better the symptoms can be managed. But current tests can give ambiguous results that do not reflect disease progression. Today, in ACS Central Science, researchers reveal a new type of sweat test that can overcome this challenge. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 31, 2017 Category: International Medicine & Public Health Source Type: news

Scientists discover biomarkers which could lead to better treatments for CF patients
(McMaster University) Researchers have identified two new biological markers of cystic fibrosis (CF), a genetic disease which affects children and young adults, leaving them with lifelong health complications including digestive problems and persistent lung infections.The findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 31, 2017 Category: Biology Source Type: news

Aradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
HAYWARD, Calif.--(BUSINESS WIRE) July 27, 2017 -- Aradigm Corporation (NASDAQ: ARDM) (the " Company " ) today announced it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq ™ for the treatment of... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 27, 2017 Category: Drugs & Pharmacology Source Type: news

As more adults are diagnosed with cystic fibrosis, radiologists look for patterns
(American Roentgen Ray Society) Marked improvements have been made over the past few decades in managing cystic fibrosis, but as more adults are diagnosed with the disease radiologists can do more to monitor the wide spectrum of CF in adults, including nonclassic imaging findings, according to an article published in the July 2017 issue of the American Journal of Roentgenology (AJR). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 26, 2017 Category: International Medicine & Public Health Source Type: news

Antabio to develop treatment for Pseudomonas infections in cystic fibrosis patients
French biopharmaceutical company Antabio has secured a non-dilutive funding to accelerate the development of a new small molecule drug to treat chronic Pseudomonas infections in cystic fibrosis patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 25, 2017 Category: Pharmaceuticals Source Type: news

New hope in battle to find cystic fibrosis cure
Professor Jane Davies, honorary consultant in paediatric medicine at London ’s Royal Brompton Hospital, said if the ‘very, very early’ results held up, triple-therapies could be used to across the world. (Source: the Mail online | Health)
Source: the Mail online | Health - July 23, 2017 Category: Consumer Health News Source Type: news

Vertex Reports Positive Results for Cystic Fibrosis Triple Combos Vertex Reports Positive Results for Cystic Fibrosis Triple Combos
Vertex Pharmaceuticals Inc on Tuesday said three different triple combinations of cystic fibrosis treatments significantly improved patient lung function in clinical trials, bolstering its goal of a therapy that could help up to 90 percent of patients with the life-shortening lung disease.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 19, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Vertex Pharma shares hit life high as cystic fibrosis data wows
(Reuters) - Shares of Vertex Pharmaceuticals Inc soared to touch a record high on Wednesday, a day after the drugmaker revealed data on its triple combinations of cystic fibrosis (CF) treatments that wowed both analysts and investors. (Source: Reuters: Health)
Source: Reuters: Health - July 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pharma Technology Focus – Issue 61
In this issue: The UK ’s healthcare spending problem, PhRMA’s new R&D spending requirements, undermining supply chain security by importing foreign drugs, milestone cystic fibrosis trials, a personalised treatment approach for panic disorder, and more … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 19, 2017 Category: Pharmaceuticals Source Type: news

Cystic fibrosis: searching for a breakthrough
There are exciting years ahead for the treatment of cystic fibrosis (CF). This inherited autosomal recessive genetic disorder has proven to be incredibly tough for drug developers, with research efforts hampered by the formidable scientific challenge … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news

Vertex spikes on good news for cystic fibrosis drugs
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 18, 2017 Category: Pharmaceuticals Source Type: news

Vertex reports positive results for cystic fibrosis triple combos
(Reuters) - Vertex Pharmaceuticals Inc said on Tuesday three different triple combinations of cystic fibrosis treatments significantly improved patient lung function in clinical trials, bolstering its goal of a therapy that could help up to 90 percent of patients with the life-shortening lung disease. (Source: Reuters: Health)
Source: Reuters: Health - July 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Vertex cystic fibrosis drug cocktails appear to hit the mark in trials
Shares of Vertex Pharmaceuticals soared in after-hours trading Tuesday after the company announced that three separate combinations of its experimental cystic fibrosis drugs had performed well in early- and mid-stage trials. The news brings the Boston-based company one important step closer to developing a treatment for nearly all patients with the lung disease. It also boosted its stock by around 25 percent by 4:30 p.m. If the stock increase holds until tomorrow's open, it would add nearly $9 billion… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 18, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Vertex cystic fibrosis drug cocktails appear to hit the mark in trials
Shares of Vertex Pharmaceuticals soared in after-hours trading Tuesday after the company announced that three separate combinations of its experimental cystic fibrosis drugs had performed well in early- and mid-stage trials. The news brings the Boston-based company one important step closer to developing a treatment for nearly all patients with the lung disease. It also boosted its stock by around 25 percent by 4:30 p.m. If the stock increase holds until tomorrow's open, it would add nearly $9 billion… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 18, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

' Just What We Dreamed.' New Vertex Drugs Show Dramatic Benefit Against Cystic Fibrosis
Three different three-drug regimens all provided dramatic results against cystic fibrosis, a fatal disease of the lungs and digestive system that afflicts 75,000 people. “This is just what we dreamed would someday happen,” says Francis Collins, the director of the National Institutes of Health (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 18, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:VRTX NASDAQ:GLPG Source Type: news

Two recent scientific advances underscore an encouraging future for precision medicine at FDA
By: Janet Woodcock, M.D. FDA helps bring precision medicine – in the form of targeted therapies — to people living with diseases that have specific genetic features. Two recent FDA drug approvals point to an encouraging future for “precision medicine” — an approach for disease treatment that tailors medical therapies, including medications, to the needs of individual patients. These approvals involve diseases resulting from particular genetic characteristics identified by laboratory testing. In mid-May, FDA announced that we expanded the approval of Kalydeco (ivacaftor), enabling a larger num...
Source: Mass Device - July 17, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog FDA Voice Source Type: news

Vertex inks another reimbursement deal in Europe for top-selling drug
Since winning FDA approval in 2015 for Orkambi, Vertex Pharmaceuticals has been slowly expanding access to the pricey cystic fibrosis drug across Europe by signing reimbursement deals with various countries. On Thursday, Boston-based Vertex (Nasdaq: VRTX) said it had inked another reimbursement deal for Orkambi, its best-selling drug, this time with officials in Italy. The agreement with the Italian Medicines Agency will make the drug available to “hundreds of eligible patients” in the country… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 13, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Bakaletz Lab biofilm work published in Proceedings of the National Academy of Sciences
(Nationwide Children's Hospital) The laboratory of Lauren Bakaletz, PhD, director, Center for Microbial Pathogenesis and vice president of basic sciences, The Research Institute at Nationwide Children's, studied the biofilm construction capabilities of nontypeable Haemophilus influenzae (NTHI), a bacterium responsible for sinusitis, pneumonia, exacerbations of cystic fibrosis and COPD, bronchitis and ear infections. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 13, 2017 Category: International Medicine & Public Health Source Type: news

Synspira ’s therapy could boost antibiotics against drug-resistant bacteria in CF patients
Privately-held Synspira touted a study today of its inhaled glycopolymer-based therapeutic with antibiotics as a potential treatment for pulmonary infection caused by the Burkholderia cepacia complex in patients with cystic fibrosis. The study was published in PLOS One. Synspira’s lead polycationic glycopolymer, SNSP113, was studied in combination with tobramycin and meropenem. These antibiotics, as well as ceftazidime, are often used to treat Bcc infections in patients with cystic fibrosis. However, Synspira said the microbial agents have demonstrated limited efficacy in the past. Get t...
Source: Mass Device - July 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Research & Development Respiratory synspira Source Type: news

Celebrating 10 years of success for Infusion
As the business took off, more space was needed, and the company moved in 2009 to “real” office space just up the road in Haddam, CT, across the street from the Connecticut River, eventually employing a staff of 10 that year. A year later, in 2010, Infusion had doubled in size and became part of the UDG/Ashfield family. Infusion continued to grow at a steady pace into new therapeutic areas with more clients and employees, and in October 2016, Infusion left its country setting and moved into larger corporate offices in downtown Middletown, CT. Our staff now comprises 45 people and includes account executives, me...
Source: Ashfield Healthcare News - July 11, 2017 Category: Pharmaceuticals Authors: Sarah Edwards Tags: Ashfield Source Type: news

New MRI agent shows promise for tumors
Researchers from the University of Massachusetts have developed a protein-based...Read more on AuntMinnie.comRelated Reading: Is ferumoxytol the alternative to gadolinium MRI agents? Glucose-MRI technique at 7T aids tumor evaluation Short breast MRI protocol works for cancer detection Novel MRI scans could aid in cystic fibrosis MRI can replace biopsy for prostate cancer surveillance (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 7, 2017 Category: Radiology Source Type: news

​Vertex raises price of top-selling cystic fibrosis drug for first time
Vertex Pharmaceuticals has raised the price of its best-selling cystic fibrosis drug for the first time, in a move that could boost revenues at the Boston-based company. The decision by Vertex (Nasdaq: VRTX) to increase the list price of Orkambi by 5 percent, to around $273,000 per year before discounts, was first reported by Cowen analyst Phil Nadeau in a note on Wednesday morning and later confirmed by a spokeswoman for the company. Vertex had not previously ra ised the price of Orkambi, which… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 5, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Living while dying: Life when you're born with cystic fibrosis
(Source: CNN.com - Health)
Source: CNN.com - Health - July 5, 2017 Category: Consumer Health News Source Type: news

Celebrating life by confronting death
Claire Wineland has cystic fibrosis, a terminal illness, and she's working to help others understand what it's like to be sick. (Source: CNN.com - Health)
Source: CNN.com - Health - July 5, 2017 Category: Consumer Health News Source Type: news

CF patients and physicians use shared decision-making tool to determine regimens
(University of Cincinnati Academic Health Center) Physician-researchers at the University of Cincinnati have developed a computerized decision-making model to promote shared decision-making with cystic fibrosis patients. The tool takes into account patients' preferences for measures of lung function and health along with the latest medical evidence for effective treatment to help patients prioritize home treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 3, 2017 Category: International Medicine & Public Health Source Type: news

Cystic fibrosis biotech Synspira launches
California-based Synedgen has spun out its experimental cystic fibrosis treatments into a new biotech to be based in the Boston area, with an eye toward complementing existing drugs for the lung disease. The new company, called Synspira, launched on Thursday with $8 million in financing from an anonymous investor and an exclusive license to privately-held Synedgen’s preclinical program for cystic fibrosis. Synspira is operating virtually — the CEO, Synedgen chief operating officer Shenda Baker ,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 30, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Cystic fibrosis biotech Synspira launches
California-based Synedgen has spun out its experimental cystic fibrosis treatments into a new biotech to be based in the Boston area, with an eye toward complementing existing drugs for the lung disease. The new company, called Synspira, launched on Thursday with $8 million in financing from an anonymous investor and an exclusive license to privately-held Synedgen’s preclinical program for cystic fibrosis. Synspira is operating virtually — the CEO, Synedgen chief operating officer Shenda Baker ,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 30, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Synspira raises $8m for inhaled pulmonary therapies
Privately-held Synspira said today that raised $8 million from an unnamed private investor to bring its inhaled cystic fibrosis therapy into a Phase I safety study. The Boston-based company was founded earlier this year and is focused on developing inhaled therapies for pulmonary diseases, including cystic fibrosis, chronic obstructive pulmonary disease and pneumonia. Synspira holds an exclusive field license to Synedgen’s Glycomics Technology platform and its pulmonary delivery assets. Get the full story at our sister site, Drug Delivery Business News. The post Synspira raises $8m for inhaled pulmonary the...
Source: Mass Device - June 29, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Funding Roundup Respiratory synspira Source Type: news

Mount Sinai, Pfizer renew research collaboration, building on strong foundation
(The Mount Sinai Hospital / Mount Sinai School of Medicine) The Icahn School of Medicine at Mount Sinai and Pfizer Inc.'s Centers for Therapeutic Innovation (CTI) today announced the renewal of an agreement designed to identify and advance new drug candidates linked to major diseases, such as cancer, rheumatoid arthritis, Crohn's disease, colitis, heart failure, Alzheimer's disease, and cystic fibrosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 27, 2017 Category: Cancer & Oncology Source Type: news

Cystic fibrosis alters the structure of mucus in airways
(University of Iowa Health Care) Cystic fibrosis (CF) alters the structure of mucus produced in airway passages. In pigs affected by CF, mucus strands (made of MUC5B protein) are more tangled than normal, and the sheets of mucus (made of MUC5AC protein) that cover the strands are denser. These structural abnormalities may help explain why people with CF have difficulty clearing mucus from their lungs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 27, 2017 Category: International Medicine & Public Health Source Type: news

Can coffee machines and kettles spread toxic spores?
Conclusion This laboratory study suggests that under humid conditions, indoor surfaces like wallpaper may be colonised by fungi that produce toxic particles – some of which may be small enough to be inhaled. But it's important that these findings aren't taken too far out of context at this stage. The study was carried out in highly experimental circumstances where both temperature and humidity were optimised for maximal fungal growth. We can't know for sure that these circumstances would be typical of indoor environments, even bathrooms or kitchens, if they're well ventilated. The UK media has applied these findin...
Source: NHS News Feed - June 26, 2017 Category: Consumer Health News Tags: Heart/lungs Lifestyle/exercise Source Type: news

How a woman with cystic fibrosis defied expectations
Janka Penther was born with cystic fibrosis (CF), a crippling genetic condition, and doctors had told her she wouldn't live past 21 years old. When she hit 30, she was planning her own funeral. (Source: the Mail online | Health)
Source: the Mail online | Health - June 25, 2017 Category: Consumer Health News Source Type: news

UCLA Mattel Children ’s Hospital and Miller Children’s & Women ’s Hospital plan strategic affiliation
Two leading children ’s hospitals —UCLA Mattel Children ’s Hospital, part of UCLA Health, and  Miller Children ’s& Women ’s Hospital Long Beach, part of  MemorialCare Health System— announced today their intent to form a strategic affiliation that brings together their academic, clinical and research expertise, and resources to enhance children’s health care services in Southern California.The two organizations, which share similar missions and values, plan to establish a wider geographic pediatric collaboration that strengthens and broadens their ability to offer the...
Source: UCLA Newsroom: Health Sciences - June 22, 2017 Category: Universities & Medical Training Source Type: news